AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Long processing times often stem from underwriting and documentation checks. We explain the common causes and how to minimize delays.
26,998 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
When a CEO buys thousands of shares, investors take note. This article breaks down the 74,000-share purchase by Energ...
A week of silence fuels speculation and headlines. This article breaks down the money side of celebrity rumors, from ...
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Artificial intelligence is reshaping how we build and defend crypto networks. Discover the ideas behind AI-assisted v...
A routine stop at a Walmart in Michigan grew into a wider look at retail fraud across several counties. This article ...
As AI demand accelerates, one company stands out for investors: TSMC. This article explains why the so-called tsmc mo...
Rivian just raised guidance, signaling progress in its production ramp. Yet the stock reaction was bearish, underscor...
Nova Measuring Instruments rode an 80% gain in the past year, but a big insider sale prompts question. This guide bre...
Sotera Health has delivered a solid return over the last 12 months. Yet a sizable fund recently unloaded millions of ...
ARTY posted a 12-month gain of 28.3%, topping QQQ's 14.3% and SPY's 13.7%, as AI infrastructure exposure draws buyers...
Insider buying can hint at confidence from leadership, but it isn’t a crystal ball. This guide explains how to interp...